Modern Capacities of Diagnostics and Surgery Treatment of the Recurrent Gastric Cancer
The Advanced Science Journal
Gastric cancer is one of the most widespread oncology diseases of the world. The aim of this research is to analyze direct and end results of medicated treatment of gastric recurrent cancer with use of Oncomarker CA 72-4. 129 surgically operated patients were investigated after having recidive gastric cancer. They had hospital care at the Department of abdominal oncology of the National Scientific Oncology Centre of the Ministry of Healthcare of the Republic of Uzbekistan during period of
... 013. Out of that amount of patients 18 (13,9%) had recidive after having proximal subtotal partial gastrectomy, 89(69%) -distal subtotal partial gastrectomy, 22(17,1%) -full gastrectomy. Out of 89 most of patients 66(74,1%) had preceded operation of Bilrot-I of distal subtotal partial gastrectomy and rest of them 23(25,9%) -Bilrot-II. According to sexual characters males were 93(72,1%), females -36(27,9%). Age criteria were torn between 24 and 79 years. All patients were operated due to gastric cancer without covering of the principals of oncologic radicalism. Out of 129 patients 104(80,6%) patients had the first surgical interferences at the different general surgery clinics and only 25 (19,4%) operations were made at the oncologic clinics. 13(10,1%) patients had anatomic structure of well-differentiated adenocarcinoma, 19(14,7%) -minor-differentiated, 68 (52,7%) -law-differentiated, 29 (22,5%) -colloid and poorly-differentiated carcinoma. Dynamic overview with use of Oncomarker CA-72-4 helps to detect recurring at yearly stages of its developing more than 5 months before its clinic manifestation. Evidently that detecting of recidive at yearly stage and its well-timed occasional radical fast treatment gives better direct as well as forthcoming results of surgery treatment of the patients with recidive gastric cancer. The most effective method of treatment resectable recidive stump cancer is surgical interferences which include standard and combined extirpation of gastric remnant. This brings to rise rates of 1-year survival up to 73,2%, 2-years survival up to 41,1% and 3-years and more than it up to 19,6% in such cases survival after nonradical operations of 3-6 months comes to 64,3%.